Genentech

dominoes stop stall halt end red
Biotech

Genentech drug fails rare disease study, raising obesity questions

Genentech will not push anti-myostatin antibody emugrobart into phase 3 for two muscle-wasting diseases after it failed to improve muscle growth.
Darren Incorvaia Mar 20, 2026 2:11pm
Stop sign and red lights at traffic intersection

Genentech shreds RIPK1 inhibitor after ph. 2 failure

Mar 19, 2026 2:48pm
Completing steps towards success checkmark on cubes symbolizing progress

Roche reports pivotal MS win, but deaths add to safety questions

Mar 2, 2026 6:00am
Completing steps towards success checkmark on cubes symbolizing progress

Roche unveils data behind BTK inhibitor's phase 3 MS win

Feb 9, 2026 7:00am
Grouping of tiles with human figures on them being separated representing layoffs

Genentech cut at least 489 jobs last year, new filing reveals

Feb 6, 2026 1:38pm
RNA Concept 3D Render

Roche continues RNA return with $1.7B deal for Sanegene drug

Feb 2, 2026 8:35am